Regeneron Pharmaceuticals, Inc. REGN
We take great care to ensure that the data presented and summarized in this overview for REGENERON PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding REGN
View all-
Vanguard Group Inc Valley Forge, PA8.93MShares$8.77 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$8.42 Billion0.19% of portfolio
-
Jpmorgan Chase & CO New York, NY7.73MShares$7.59 Billion0.68% of portfolio
-
State Street Corp Boston, MA4.84MShares$4.76 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.65MShares$4.57 Billion0.76% of portfolio
-
Capital International Investors Los Angeles, CA3.13MShares$3.07 Billion0.62% of portfolio
-
Geode Capital Management, LLC Boston, MA2.38MShares$2.33 Billion0.21% of portfolio
-
Dodge & Cox San Francisco, CA2.36MShares$2.32 Billion1.39% of portfolio
-
Franklin Resources Inc San Mateo, CA1.69MShares$1.66 Billion0.54% of portfolio
-
Morgan Stanley New York, NY1.34MShares$1.32 Billion0.1% of portfolio
Latest Institutional Activity in REGN
Top Purchases
Top Sells
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Insider Transactions at REGN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 17
2024
|
Leonard S Schleifer Bd. Co-Chair, President & CEO |
SELL
Open market or private sale
|
Direct |
22,830
-2.33%
|
$22,350,570
$979.64 P/Share
|
May 16
2024
|
George Yancopoulos Bd. Co-Chair, President & CSO |
SELL
Open market or private sale
|
Direct |
50,000
-0.51%
|
$48,600,000
$972.93 P/Share
|
May 15
2024
|
George Yancopoulos Bd. Co-Chair, President & CSO |
SELL
Open market or private sale
|
Direct |
50,000
-0.23%
|
$48,850,000
$977.45 P/Share
|
May 15
2024
|
Leonard S Schleifer Bd. Co-Chair, President & CEO |
SELL
Open market or private sale
|
Direct |
10,941
-0.27%
|
$10,765,944
$984.03 P/Share
|
May 14
2024
|
Leonard S Schleifer Bd. Co-Chair, President & CEO |
SELL
Open market or private sale
|
Direct |
25,000
-2.9%
|
$24,475,000
$979.63 P/Share
|
May 13
2024
|
Leonard S Schleifer Bd. Co-Chair, President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
144,433
-25.0%
|
$140,966,608
$976.79 P/Share
|
May 13
2024
|
Leonard S Schleifer Bd. Co-Chair, President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
203,204
+26.02%
|
$81,078,396
$399.66 P/Share
|
May 03
2024
|
George L Sing Director |
SELL
Payment of exercise price or tax liability
|
Direct |
877
-3.09%
|
$826,134
$942.53 P/Share
|
May 03
2024
|
George L Sing Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+6.59%
|
$826,000
$413.33 P/Share
|
May 01
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.02%
|
$90,100
$901.47 P/Share
|
May 01
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
250
-1.9%
|
$222,250
$889.41 P/Share
|
Apr 29
2024
|
George Yancopoulos Bd. Co-Chair, President & CSO |
BUY
Bona fide gift
|
Indirect |
18,148
+50.0%
|
-
|
Apr 29
2024
|
George Yancopoulos Bd. Co-Chair, President & CSO |
SELL
Bona fide gift
|
Indirect |
36,296
-100.0%
|
-
|
Apr 01
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
250
-1.86%
|
$241,000
$964.73 P/Share
|
Apr 01
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.06%
|
$96,100
$961.56 P/Share
|
Mar 14
2024
|
Andrew J Murphy EVP Research |
SELL
Open market or private sale
|
Direct |
5,783
-0.8%
|
$5,540,114
$958.88 P/Share
|
Mar 13
2024
|
Andrew J Murphy EVP Research |
SELL
Payment of exercise price or tax liability
|
Direct |
14,217
-20.81%
|
$13,804,707
$971.82 P/Share
|
Mar 13
2024
|
Andrew J Murphy EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+22.65%
|
$7,980,000
$399.66 P/Share
|
Mar 01
2024
|
Marion Mc Court EVP Commercial |
SELL
Open market or private sale
|
Direct |
358
-2.6%
|
$346,186
$967.5 P/Share
|
Mar 01
2024
|
Arthur F Ryan Director |
SELL
Open market or private sale
|
Direct |
100
-0.03%
|
$97,800
$978.23 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 15.7K shares |
---|---|
Exercise of conversion of derivative security | 729K shares |
Bona fide gift | 18.1K shares |
Payment of exercise price or tax liability | 533K shares |
---|---|
Open market or private sale | 296K shares |
Bona fide gift | 37.7K shares |